Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6847800 | 0.92 | CYP11B2 (0.51) | CYP11B2CYP11B1MAPTCYP17A1CYP19A1 | |
| SCHEMBL6660867 | 0.90 | MAPT (0.46) | CYP11B2CYP11B1MAPTGRIN1GRIN2B | |
| SCHEMBL6656090 | 0.89 | CYP11B2 (0.50) | CYP11B2CYP11B1MAPTCYP17A1CYP1A2 | |
| SCHEMBL6846125 | 0.88 | CYP11B2 (0.59) | CYP11B2CYP11B1MAPTCYP17A1CYP1A2 | |
| SCHEMBL6655119 | 0.86 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP17A1CYP19A1CYP3A4 | |
| SCHEMBL6656915 | 0.84 | CYP11B1 (0.50) | CYP11B2CYP11B1MAPTGRIN1GRIN2B | |
| SCHEMBL6657580 | 0.84 | ROCK2 (0.48) | CYP11B2CYP11B1MAPTGRIN1GRIN2B | |
| SCHEMBL6966876 | 0.84 | CYP11B2 (0.53) | CYP11B2CYP11B1MAPTCYP17A1CYP19A1 | |
| SCHEMBL22515748 | 0.84 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP17A1CYP19A1CYP3A4 | |
| SCHEMBL6658095 | 0.84 | NR3C1 (0.50) | CYP11B2CYP11B1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885CYP11B1 30/4885MAPT 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.